InsidersTradesSigma
GENFIT Stock: price and directors' dealings · France · AMF
Follow the GENFIT stock price and the full directors' dealings record of the company, a listed equity based in France. Shares trade on FR FR, under the oversight of AMF. Operating in the Healthcare & Pharma sector, GENFIT has recorded 9 reports. Market capitalisation: €516m. The latest transaction was disclosed on 4 March 2026 (Exercice). Among the most active insiders: Pascal Prigent. The full history is accessible without an account.
9
Insider Decl.
0
Thresholds
€181,391
6 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate GENFIT Strong Buy (bullish), based on 4 analysts. Average price target: €14.00.
57Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 4 March 2026
Declarations9 total
28,958 shares@ €3.08050.020% mcap100.0% of flowOption d'achatEuronext Paris2026DD1098600
5,300 shares@ €3.67750.9% of flowActionEuronext Paris2023DD918885
Ideal exit: 2 Apr 2024 (T+270)
10,000 shares@ €3.706151.5% of flowActionEuronext Paris2023DD918358
Ideal exit: 31 Mar 2024 (T+270)
10,000 shares@ €3.69651.9% of flowActionEuronext Paris2023DD918364
Ideal exit: 1 Apr 2024 (T+270)
5,300 shares@ €3.541549.1% of flowActionEuronext Paris2023DD917873
Ideal exit: 29 Mar 2024 (T+270)
4 shares0ActionEuronext Paris2022DD864906
2,000 shares0ActionEuronext Paris2022DD864869
10,000 shares@ €3.4248.1% of flowActionEuronext Paris2022DD824658
Ideal exit: 27 Nov 2022 (T+270)
10,000 shares@ €3.491248.5% of flowActionEuronext Paris2022DD824665
Ideal exit: 28 Nov 2022 (T+270)
9 of 9 declarations
About GENFIT
GENFIT is a French biopharmaceutical company listed on Euronext Paris under the ticker GNFT and identified by ISIN FR0004163111. Founded in 1999 in France by Jean-François Mouney, now Chairman of the Board, the company has built its identity around long-standing expertise in liver diseases, with a particular emphasis on rare and severe conditions with major unmet medical needs. Its headquarters are in Loos, near Lille, and the group also maintains operations in Cambridge, Massachusetts, and Zurich, Switzerland. Over time, GENFIT has evolved from a research-focused organization into a late-stage biopharmaceutical company with a diversified R&D portfolio. Historically, the company has also demonstrated an ability to create value through strategic collaborations and licensing agreements with major pharmaceutical players, reflecting its track record in advancing programs and monetizing assets beyond internal development. GENFIT’s core business is now centered on rare and life-threatening liver diseases, with a strategic emphasis on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes multiple assets under development, built around complementary mechanisms of action and different routes of administration. In parallel, the company is pursuing additional programs in severe indications such as cholangiocarcinoma, urea cycle disorders, and certain organic acidemias. GENFIT also develops non-invasive diagnostic solutions, notably technologies aimed at detecting MASH/NASH and ammonia-related disorders, strengthening its value proposition across the full care pathway of liver disease management. The group has shown it can advance drug candidates from early discovery into late-stage clinical development and pre-commercialization, highlighted by the success of the Phase 3 ELATIVE study of elafibranor in Primary Biliary Cholangitis. From a market and financial perspective, GENFIT is positioned as a specialist niche player with strong scientific credibility and exposure to high-value medical and economic opportunities. The company has recently reinforced its international footprint and financial flexibility, notably through non-dilutive funding arrangements and revenues tied to partnerships. Its transatlantic geographic presence enables it to combine European scientific capabilities with access to the U.S. market and key biotech ecosystems. As such, GENFIT remains a growth-oriented healthcare stock whose performance is closely linked to clinical execution, regulatory milestones, and the monetization of its therapeutic and diagnostic pipeline.
